Compugen (NASDAQ:CGEN) Stock Passes Above Two Hundred Day Moving Average - Should You Sell?

Key Points

• Compugen's stock price recently crossed above its two hundred day moving average, reaching a high of $1.88 before last trading at $1.81.
• Analysts are generally pessimistic, with Wall Street Zen downgrading the stock to a "sell" rating and Weiss Ratings reiterating a "sell (d-)" rating.
• The company reported a negative earnings per share of ($0.08), missing expectations and revealing a significant contrast between actual revenue of $1.26 million and the consensus estimate of $3.95 million.

Compugen Ltd. (NASDAQ:CGEN - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.50 and traded as high as $1.88. Compugen shares last traded at $1.81, with a volume of 405,295 shares trading hands.

Analysts Set New Price Targets

CGEN has been the subject of several recent research reports. Wall Street Zen lowered Compugen from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Compugen in a report on Wednesday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Compugen currently has a consensus rating of "Hold" and a consensus price target of $4.00.

Compugen Price Performance

The business's 50 day moving average price is $1.47 and its 200-day moving average price is $1.50. The company has a market cap of $161.52 million, a P/E ratio of -8.23 and a beta of 2.61.

Compugen (NASDAQ:CGEN - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). Compugen had a negative net margin of 87.45% and a negative return on equity of 34.77%. The firm had revenue of $1.26 million during the quarter, compared to the consensus estimate of $3.95 million. As a group, research analysts forecast that Compugen Ltd. will post -0.03 EPS for the current year.

Institutional Trading of Compugen

Several institutional investors and hedge funds have recently made changes to their positions in CGEN. US Bancorp DE bought a new stake in shares of Compugen during the 1st quarter valued at $29,000. Calamos Wealth Management LLC acquired a new position in Compugen in the 1st quarter worth $43,000. Franklin Resources Inc. acquired a new position in Compugen in the 2nd quarter worth $56,000. R Squared Ltd acquired a new position in shares of Compugen during the 2nd quarter worth about $71,000. Finally, Osaic Holdings Inc. boosted its stake in shares of Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company's stock worth $78,000 after buying an additional 34,045 shares during the last quarter. Institutional investors own 12.22% of the company's stock.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.